Braveheart Bio is a Bay Area–based biopharmaceutical company pioneering best-in-class therapies for cardiovascular disease. Our lead program is a next-generation myosin inhibitor, licensed from Hengrui Pharma, being developed to transform the treatment of hypertrophic cardiomyopathy (HCM)—the most common inherited cardiac disease. Currently in Phase 3 clinical development in China for the more common obstructive form of HCM, our candidate has demonstrated a compelling clinical profile that may position it as a best-in-class therapy with meaningful differentiation. With a proven leadership team, a strong financial foundation, and a high-value late-stage asset, Braveheart Bio represents an outstanding opportunity for ambitious, mission-driven professionals to make a tangible impact in a high-profile and rapidly evolving therapeutic area. The Director of Regulatory Affairs will serve as the Global Regulatory Lead and provide regulatory leadership for Braveheart Bio’s Phase 3 hypertrophic cardiomyopathy (HCM) program. Reporting into the Vice President of Regulatory, Safety & Pharmacovigilance, this individual will be responsible for developing and executing global regulatory strategies to support late-stage clinical development, registration readiness, and lifecycle management for our HCM asset. In addition, this role will support the implementation and optimization of regulatory systems and infrastructure as Braveheart continues to scale.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director